Log in to save to my catalogue

A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous ce...

A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous ce...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9855315

A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous cell carcinoma of the anal canal (the JROSG 10–2 trial)

About this item

Full title

A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous cell carcinoma of the anal canal (the JROSG 10–2 trial)

Publisher

England: Oxford University Press

Journal title

Journal of radiation research, 2023-01, Vol.64 (1), p.154-161

Language

English

Formats

Publication information

Publisher

England: Oxford University Press

More information

Scope and Contents

Contents

This study assessed the efficacy of chemoradiotherapy for squamous cell carcinoma of the anal canal (SCCAC). Patients with T1–4N0-3M0 SCCAC received chemoradiotherapy with 5-fluorouracil (5-FU, 800 mg/m2/day, 96-h infusion) and mitomycin-C (MMC, 10 mg/m2 bolus). Patients treated with 3-dimensional conformal radiotherapy (3D-CRT) or intensity-modula...

Alternative Titles

Full title

A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous cell carcinoma of the anal canal (the JROSG 10–2 trial)

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9855315

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9855315

Other Identifiers

ISSN

0449-3060

E-ISSN

1349-9157

DOI

10.1093/jrr/rrac069

How to access this item